CAMBRIDGE, Mass.--(BUSINESS WIRE)--FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that researchers will present results from the successful pivotal trial of tafamidis meglumine (tafamidis) at the 62nd American Academy of Neurology (AAN) Annual Meeting in Toronto. Tafamidis, the company’s lead compound, is being investigated as a disease modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressive and life-threatening neurodegenerative disease that affects an estimated 10,000 patients worldwide.
